Philips aims to broaden the reach of its digital patient monitoring platforms, from inside the hospital out to the home, through a $2.8 billion acquisition deal for BioTelemetry and its wearable heart-tracking devices.

Mereo BioPharma is teaming up with Ultragenyx to work on its rare genetic bone disease drug.

Penny stock biotech Seneca Biopharma has found a lifeline in privately owned Leading BioSciences as it merges with the biotech.

The Nasdaq has been a hopping place this year, with new biotechs adding their symbol to the ticker every week and others flooding the market with more stock. Every time positive trial data is reported or a nod from the FDA comes through, stock prices soar.

The U.S. Food and Drug Administration (FDA) granted Novartis’ experimental drug iptacopan Breakthrough Therapy designation in paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder.

COPENHAGEN, Denmark — Evaxion Biotech A/S, a clinical-stage biotechnology company developing AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the appointment of previously practicing commercial, technology and corporate lawyer Marianne Søgaard as Chairwoman of the Board of Directors.

Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Five years later, the Swiss pharma is helping itself to the rest of Cadent’s pipeline in a deal worth $210 million upfront but that could net the latter up to $770 million in total.

Sage Therapeutics is embarking on a new chapter in its development following its $1.5 billion alliance with Biogen last month, and that challenge will now be met by a new CEO.

Neurogene has raised $115 million in a second-round financing that will accelerate its plans to start clinical trials of a range of gene therapies for inherited neurological diseases, initially focusing on a form of Batten disease.

Michael Bruce, Ph.D., has worked for the likes of Pfizer and CRISPR Therapeutics, but now he’s the CEO of what he believes will be the future in medicine: Exo Therapeutics. The company raised $25 million (PDF) in series A funding to back a pipeline of drugs that bind their enzyme targets at their exosites. The goals are to create better medicines without harmful side effects and to hit targets that were previously considered undruggable.